ProBioGen enters into Agreement with Nobelpharma for Manufacturing Process Development of their Vaccine Project


ProBioGen AG is delighted to announce the signing of a service agreement for Nobelpharma’s highly relevant vaccine project.

Earlier work confirmed already the versatility and benefit of ProBioGen’s vaccine development platform, consisting of the…


FyoniBio® the service branch of Glycotop


With beginning of 2021 Glycotope will offer its Contract Development Organization (CDO) and Clinical Lab services under the brand name FyoniBio®, the service branch of Glycotope.

With 20 years of history in biopharma development FyoniBio® is in a…


Genetic factors influencing the course of a SARS-CoV-2 infection

Epidemiologic investigation of peptide signatures, immunity, genetic predisposition, and alterations in SARS-CoV-2 (EPI-Dx)


ProBioGen licenses GlymaxX® Technology to Sanofi

Enhancement of Target Cell Killing for Innovative Therapies


New cancer-fighting immunotherapy enters clinical trials

Researchers from the MDC and Charité have developed a new gene therapy based around a special T-cell receptor that helps the immune system effectively recognize and fight cancer cells. The safety of the novel therapy is now being tested on patients…


GILUPI and SCIENION announce Collaboration for the Development of Single-Cell CTC Analysis

GILUPI GmbH and SCIENION AG announced on March 18that the companies intend to intensify their collaboration in the field of single circulating tumor cell (CTC) analysis. CTCs are rare cells that can be found in the peripheral blood of cancer…


Early warning system for intensive care units

Life-threatening situations occur time and again in an intensive care unit. To make sure that doctors can intervene in time, a team at the German Heart Center Berlin (DHZB) has developed AI-based software that regularly evaluates all monitoring data…


Improving durability of dental structures

How can dental restorations – such as fillings and crowns – be made to last longer? A new research group centered at Charité – Universitätsmedizin Berlin and Technische Universität (TU) Berlin plans to address this topic by utilizing approaches from…


First-in-human clinical study results


Cardio-microcurrent device for chronic heart failure: first-in-human clinical study

Most devices for treating ambulatory Class II and III heart failure are linked to electrical pulses. However, a steady electric potential gradient is also…


Prof. Andreas Lendlein becomes an AIMBE-Fellow | Great honor for the HZG-Institute of Active Polymers

Great honor for Helmholtz-Zentrum Geesthacht (HZG): The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of Professor Andreas Lendlein, Director of the HZG Institute of Active Polymers in Teltow, as a…

Show more items